| Identification | Back Directory | [Name]
3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[4-[[7-[[7-(hydroxyamino)-7-oxoheptyl]oxy]-6-methoxy-4-quinolinyl]oxy]phenyl]-2-oxo- | [CAS]
2439175-23-0 | [Synonyms]
c-Met/HDAC-IN-3
3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[4-[[7-[[7-(hydroxyamino)-7-oxoheptyl]oxy]-6-methoxy-4-quinolinyl]oxy]phenyl]-2-oxo- | [Molecular Formula]
C34H35FN4O7 | [MOL File]
2439175-23-0.mol | [Molecular Weight]
630.66 |
| Hazard Information | Back Directory | [Uses]
c-Met/HDAC-IN-3 (Compound 15f) is a dual c-Met and HDAC inhibitor with IC50 values of 12.50 nM and 26.97 nM against c-Met and HDAC1, respectively. c-Met/HDAC-IN-3 induces apoptosis and cause cell cycle arrest in G2/M phase[1]. | [IC 50]
HDAC1: 26.97 nM (IC50) | [References]
[1] Hu H, et al. Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy. Bioorg Chem. 2020 Aug;101:103970. DOI:10.1016/j.bioorg.2020.103970 |
|
|